Voltage-gated potassium (Kv) channels formed by Kv7 (KCNQ) α-subunits are recognized as crucial for vascular smooth muscle function, in addition to their established roles in the heart (Kv7.1) and the brain (Kv7.2-5). In vivo, Kv7 α-subunits are often regulated by KCNE subfamily ancillary (β) subunits. We investigated the effects of targeted germline Kcne4 deletion on mesenteric artery reactivity in adult male and female mice. Kcne4 deletion increased mesenteric artery contractility in response to α-adrenoceptor agonist methoxamine, and decreased responses to Kv7.2-7.5 channel activator ML213, in male but not female mice. In contrast, Kcne4 deletion markedly decreased vasorelaxation in response to isoprenaline in both male and female mice. Kcne4 expression was 2-fold lower in the female versus the male mouse mesenteric artery, and Kcne4 deletion elicited only moderate changes of other Kcne transcripts, with no striking sex-specific differences. However, Kv7.4 protein expression in females was twice that in males, and was reduced in both sexes by Kcne4 deletion. Our findings confirm a crucial role for KCNE4 in regulation of Kv7 channel activity to modulate vascular tone, and provide the first known molecular mechanism for sex-specificity of this modulation that has important implications for vascular reactivity and may underlie sex-specific susceptibility to cardiovascular diseases.

Keywords:
Kv7 channels, KCNE subunits, KCNE4, KCNQ, Potassium channels, Vascular physiology, Smooth muscle
1.
Abbott GW, Goldstein SA: A superfamily of small potassium channel subunits: form and function of the MinK-related peptides (MiRPs). Q Rev Biophys 1998;31:357-398.
2.
Jepps TA, Carr G, Lundegaard PR, Olesen SP, Greenwood IA: Fundamental role for the KCNE4 ancillary subunit in Kv7.4 regulation of arterial tone. J Physiol 2015;593:5325-5340.
3.
Ng FL, Davis AJ, Jepps TA, Harhun MI, Yeung SY, Wan A, Reddy M, Melville D, Nardi A, Khong TK, Greenwood IA: Expression and function of the K+ channel KCNQ genes in human arteries. Br J Pharmacol 2011;162:42-53.
4.
Stott JB, Jepps TA, Greenwood IA: K(V)7 potassium channels: a new therapeutic target in smooth muscle disorders. Drug Discov Today 2014;19:413-424.
5.
Jepps TA, Bentzen BH, Stott JB, Povstyan OV, Sivaloganathan K, Dalby-Brown W, Greenwood IA: Vasorelaxant effects of novel Kv 7.4 channel enhancers ML213 and NS15370. Br J Pharmacol 2014;171:4413-4424.
6.
Yeung SY, Pucovský V, Moffatt JD, Saldanha L, Schwake M, Ohya S, Greenwood IA: Molecular expression and pharmacological identification of a role for Kv7 channels in murine vascular reactivity. Br J Pharmacol 2007;151:758-770.
7.
Chadha PS, Jepps TA, Carr G, Stott JB, Zhu HL, Cole WC, Greenwood IA: Contribution of kv7.4/kv7.5 heteromers to intrinsic and calcitonin gene-related peptide-induced cerebral reactivity. Arterioscler Thromb Vasc Biol 2014;34:887-893.
8.
Brueggemann LI, Mackie AR, Cribbs LL, Freda J, Tripathi A, Majetschak M, Byron KL: Differential protein kinase C-dependent modulation of Kv7.4 and Kv7.5 subunits of vascular Kv7 channels. J Biol Chem 2014;289:2099-2111.
9.
Zhong XZ, Harhun MI, Olesen SP, Ohya S, Moffatt JD, Cole WC, Greenwood IA: Participation of KCNQ (Kv7) potassium channels in myogenic control of cerebral arterial diameter. J Physiol 2010;588:3277-3293.
10.
Jepps TA, Chadha PS, Davis AJ, Harhun MI, Cockerill GW, Olesen SP, Hansen RS, Greenwood IA: Downregulation of Kv7.4 channel activity in primary and secondary hypertension. Circulation 2011;124:602-611.
11.
Chadha PS, Zunke F, Zhu HL, Davis AJ, Jepps TA, Olesen SP, Cole WC, Moffatt JD, Greenwood IA: Reduced KCNQ4-encoded voltage-dependent potassium channel activity underlies impaired β-adrenoceptor-mediated relaxation of renal arteries in hypertension. Hypertension 2012;59:877-884.
12.
Khanamiri S, Soltysinska E, Jepps TA, Bentzen BH, Chadha PS, Schmitt N, Greenwood IA, Olesen SP: Contribution of Kv7 channels to basal coronary flow and active response to ischemia. Hypertension 2013;62:1090-1097.
13.
Stott JB, Barrese V, Jepps TA, Leighton EV, Greenwood IA: Contribution of Kv7 channels to natriuretic peptide mediated vasodilation in normal and hypertensive rats. Hypertension 2015;65:676-682.
14.
Stott JB, Povstyan OV, Carr G, Barrese V, Greenwood IA: G-protein βγ subunits are positive regulators of Kv7.4 and native vascular Kv7 channel activity. Proc Natl Acad Sci USA 2015;112:6497-6502.
15.
Mani BK, Robakowski C, Brueggemann LI, Cribbs LL, Tripathi A, Majetschak M, Byron KL: Kv7.5 potassium channel subunits are the primary targets for PKA-dependent enhancement of vascular smooth muscle Kv7 currents. Mol Pharmacol 2016;89:323-334.
16.
Vassalle C, Simoncini T, Chedraui P, Pérez-López FR: Why sex matters: the biological mechanisms of cardiovascular disease. Gynecol Endocrinol 2012;28:746-751.
17.
Gonzales RJ: Androgens and the cerebrovasculature: modulation of vascular function during normal and pathophysiological conditions. Pflugers Arch 2013;465:627-642.
18.
Rossi P, Francès Y, Kingwell BA, Ahimastos AA: Gender differences in artery wall biomechanical properties throughout life. J Hypertens 2011;29:1023-1033.
19.
Sandberg K, Ji H: Sex differences in primary hypertension. Biol Sex Differ 2012;3:7.
20.
Doumas M, Papademetriou V, Faselis C, Kokkinos P: Gender differences in hypertension: myths and reality. Curr Hypertens Rep 2013;15:321-330.
21.
Dasinger JH, Alexander BT: Gender differences in developmental programming of cardiovascular diseases. Clin Sci (Lond) 2016;130:337-348.
22.
Lopes RA, Neves KB, Carneiro FS, Tostes RC: Testosterone and vascular function in aging. Front Physiol 2012;3:89.
23.
Crump SM, Hu Z, Kant R, Levy DI, Goldstein SA, Abbott GW: Kcne4 deletion sex- and age-specifically impairs cardiac repolarization in mice. FASEB J 2016;30:360-369.
24.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-408.
25.
Mackie AR, Brueggemann LI, Henderson KK, Shiels AJ, Cribbs LL, Scrogin KE, Byron KL: Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance. J Pharmacol Exp Ther 2008;325:475-483.
26.
Mills TA, Greenwood SL, Devlin G, Shweikh Y, Robinson M, Cowley E, Hayward CE, Cottrell EC, Tropea T, Brereton MF, Dalby-Brown W, Wareing M: Activation of KV7 channels stimulates vasodilatation of human placental chorionic plate arteries. Placenta 2015;36:638-644.
27.
Yevenes GE, Moraga-Cid G, Guzmán L, Haeger S, Oliveira L, Olate J, Schmalzing G, Aguayo LG: Molecular determinants for G protein betagamma modulation of ionotropic glycine receptors. J Biol Chem 2006;281:39300-39307.
28.
Moreno-Domínguez A, Cidad P, Miguel-Velado E, López-López JR, Pérez-García MT: De novo expression of Kv6.3 contributes to changes in vascular smooth muscle cell excitability in a hypertensive mice strain. J Physiol 2009;587:625-640.
29.
Strutz-Seebohm N, Seebohm G, Fedorenko O, Baltaev R, Engel J, Knirsch M, Lang F: Functional coassembly of KCNQ4 with KCNE-beta-subunits in Xenopus oocytes. Cell Physiol Biochem 2006;18:57-66.
30.
Roura-Ferrer M, Etxebarria A, Solé L, Oliveras A, Comes N, Villarroel A, Felipe A: Functional implications of KCNE subunit expression for the Kv7.5 (KCNQ5) channel. Cell Physiol Biochem 2009;24:325-334.
31.
Roepke TK, King EC, Purtell K, Kanda VA, Lerner DL, Abbott GW: Genetic dissection reveals unexpected influence of β subunits on KCNQ1 K+ channel polarized trafficking in vivo. FASEB J 2011;25:727-736.
32.
Reckelhoff JF: Sex steroids, cardiovascular disease, and hypertension: unanswered questions and some speculations. Hypertension 2005;45:170-174.
33.
Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM: Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 2011;97:870-875.
34.
Fukai S, Akishita M, Yamada S, Ogawa S, Yamaguchi K, Kozaki K, Toba K, Ouchi Y: Plasma sex hormone levels and mortality in disabled older men and women. Geriatr Gerontol Int 2011;11:196-203.
35.
Hyde Z, Norman PE, Flicker L, Hankey GJ, Almeida OP, McCaul KA, Chubb SA, Yeap BB: Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. J Clin Endocrinol Metab 2012;97:179-189.
36.
Kundu P, Ciobotaru A, Foroughi S, Toro L, Stefani E, Eghbali M: Hormonal regulation of cardiac KCNE2 gene expression. Mol Cell Endocrinol 2008;292:50-62.
37.
Roepke TK, Kontogeorgis A, Ovanez C, Xu X, Young JB, Purtell K, Goldstein PA, Christini DJ, Peters NS, Akar FG, Gutstein DE, Lerner DJ, Abbott GW: Targeted deletion of kcne2 impairs ventricular repolarization via disruption of I(K,slow1) and I(to,f). FASEB J 2008;22:3648-3660.
38.
Alzamora R, O'Mahony F, Bustos V, Rapetti-Mauss R, Urbach V, Cid LP, Sepulveda FV, Harvey BJ: Sexual dimorphism and oestrogen regulation of KCNE3 expression modulates the functional properties of KCNQ1 K(+) channels. J Physiol 2011;589:5091-5107.
39.
Abbott GW, Butler MH, Goldstein SA: Phosphorylation and protonation of neighboring MiRP2 sites: function and pathophysiology of MiRP2-Kv3.4 potassium channels in periodic paralysis. FASEB J 2006;20:293-301.
40.
Zhou P, Fu L, Pan Z, Ma D, Zhang Y, Qu F, Guo L, Cao J, Gao Q, Han Y: Testosterone deprivation by castration impairs expression of voltage-dependent potassium channels in rat aorta. Eur J Pharmacol 2008;593:87-91.
41.
Abbott GW: Biology of the KCNQ1 potassium channel. New J Sci DOI: 10.1155/2014/ 237431.
42.
Abbott GW: The KCNE2 K(+) channel regulatory subunit: ubiquitous influence, complex pathobiology. Gene 2015;569:162-172.
43.
Abbott GW: KCNE1 and KCNE3: the yin and yang of voltage-gated K(+) channel regulation. Gene 2016;576:1-13.
44.
Qu J, Kryukova Y, Potapova IA, Doronin SV, Larsen M, Krishnamurthy G, Cohen IS, Robinson RB: MiRP1 modulates HCN2 channel expression and gating in cardiac myocytes. J Biol Chem 2004;279:43497-43502.
45.
Liu W, Deng J, Wang G, Zhang C, Luo X, Yan D, Su Q, Liu J: KCNE2 modulates cardiac L-type Ca channel. J Mol Cell Cardiol 2014;72:208-218.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.